Industry News

A leading international developer and manufacturer of advanced and innovative hearing healthcare solutions, Denmark-based GN ReSound,  launched Resound LiNX2 in India, the world’s first full family of smart hearing aids.  The world’s smartest hearing aid, ReSound LiNX2 takes the user experience to the next level with Spatial Sense . The new Spatial Sense technology gives users a vivid sense of space and speech in top-rated sound quality.  ReSound LiNX2 is the fourth premium family of hearing aids to come out of GN ReSound’s proprietary 2.4 GHz wireless platform and builds on already industry-leading technologies in all areas of Smart Hearing (audiology, connectivity, design, and apps).

Sun Pharmaceutical Industries and AstraZeneca Pharma India  (AZPIL) have entered agreement  for distribution of AstraZeneca’s brand “Axcer”, a new brand of ticagrelor in India. This  drug is used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012. This collaboration will provide customers access to this latest generation treatment option for ACS.

The Indian Academy of Paediatrics (IAP) in partnership with HealthPhone, Ministry of Women and Child Development (MWCD), Government of India and UNICEF, announced launch of the IAP HealthPhone programme, the world's largest digital mass education programme to face the challenge of malnutrition in women and children, at the national-level in India. The programme will achieve its objectives by widely promoting and distributing four re-edited videos from the Poshan series, jointly produced by MWCD and UNICEF in 18 Indian languages. The Poshan videos address issues of status of women, the care of pregnant women and children under two, breastfeeding and the importance of balanced diet, health and simple changes in nutritional care practices that can notably enhance nutrition levels.

Glenmark Pharmaceuticals granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.

DeNovo Sciences, Inc., an innovator of cutting edge products of liquid biopsy, sign an agreement with START (South Texas Accelerated Research Therapeutics), a San Antonio based phase I medical oncology programme, one of the world’s largest of its kind with clinical trial sites on three continents.  As per agreement, START will collect blood samples of  cancer patients and use DeNovo instruments and reagents for circulating tumour cells (CTC) enrichment and purification. This will further will then be sent to a large genomics lab for whole genome sequencing. In addition, START and DeNovo have signed a separate agreement to test the ability of Denovo CTC platform to capture CTCs for use in patient derived xenograft (PDX) mice models for drug discovery and biomarker development purposes.

Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs.,  has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of company's work in developing Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).  This award was presented to Vanda at the 2015 Portraits of Courage Gala in Washington D.C. on 18th May.

US Food and Drug Administration (FDA) has approved Eli Lilly and Company Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro 100 units/mL) Humalog U-200 KwikPen is used to improve glycemic control in people with type 1 and type 2 diabetes.

The Food and Drug Administration (FDA)  has approved Actavis' Viberzi (eluxadoline) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).
IBS-D is a multifactorial disorder marked by recurrent abdominal pain or discomfort and altered bowel function that affects as many as 15 million adult Americans, impacting about twice as many women as men. There are few treatment options available for IBS-D, particularly options that relieve both the diarrhea and abdominal pain associated with IBS-D.